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Present cancer treatment strategies are based on the
assumption that a therapy may work (“response”) or not
work (“no-response”). In patients who do not respond to
therapy, the course of disease is usually believed to be the
same as without treatment. However, the existing evidence
suggests that current cancer treatment modalities may also
have a cancer-promoting effect. In this presentation, the
data will be reviewed suggesting that tumour growth /
metastatic spread can be stimulated and survival of patients
in certain subgroups can be decreased by surgery, irradia-
tion, chemotherapy and immunotherapy. Thus, results of
cancer treatment may be improved by detecting and using
biomarkers that correlate with positive or negative thera-
peutic effect. Small comparative trials based on such
biomarkers rather than large phase III trials may be preferable
for testing efficacy of new drugs. Ignoring biomarkers
that correlate with positive or negative therapeutic effect
may not be compatible with the ethical principle “First
Do No Harm”.
THE USE OF VARIATIONS IN PROTEOMES
TO PREDICT, PREVENT, AND PERSONALIZE
TREATMENT FOR CLINICALLY NONFUNCTIONAL
PITUITARYADENOMAS
Zhan X, Desiderio DM
Department of Neurology, University of Tennessee Health
Science Center, 847 Monroe Avenue, Room 108, Memphis,
TN 38120 USA
The traditional assessment of the level of one serum-
hormone is difficult to detect clinically nonfunctional (NF)
pituitary adenomas; furthermore, no effective chemical
therapy exists to treat an NF pituitary adenoma. An NF
pituitary adenoma contains highly heterogeneous cell types
[1] that are the distinguishing pathophysiological basis that
causes the proteomic variation. In combination with
multiple endogenous and exogenous factors, that proteomic
variation is the basis for personalized patient treatment. A
more accurate multiple-parameter global systematic strategy
will replace the limited single-factor strategy in the
prediction, prevention, and personalized treatment of NF
pituitary adenomas. The global-proteomic strategy offers
the promise for the multiple-parameter assessment for the
predictive diagnosis, measurement of preventive and
therapeutic response, and personalized patient treatment.
The diagram of the use of proteomic variation to predict,
prevent, and personalize treatment of NF adenomas is
shown (Fig. 1). A tissue proteomic-variation study would
lead to the accurate molecular classification of an NF
adenoma that will contribute to identification of personal-
ized patients. Modalities of the altered tissue-proteome of a
personalized patient will realize the personalized treatment
of NF pituitary adenomas. This therapeutic response will be
assessed with body-fluid (serum and/or CSF) proteomic/
peptidomic variations to determine whether tumor progres-
sion is inhibited or halted. The high-risk population that
might develop an NF pituitary adenoma will be determined
with a predictive diagnosis strategy—body-fluid (serum
and/or CSF) proteomic/peptidomic variations. Modalities of
the altered tissue-proteome of the high-risk population will
realize the interventional prevention. This preventive
response will be assessed with body-fluid (serum and/or
CSF) proteomic/peptidomic variations to determine the
preventive effects and whether tumor occurrence is halted.
The serum/cerebrospinal fluid (CSF) proteomic/peptidomic
variation would lead to serum/CSF protein/peptide pattern
diagnostics, and the protein/antibody microarray for the
predictive diagnosis and measurement of interventional
prevention and personalized therapeutic response.
Proteomic variations offer numerous opportunities to predict,
prevent, and provide a personalized treatment (PPPM) for NF
pituitary adenomas. Currently, whole tissue-proteome variations
(protein expression; hormone isoforms; modifications) are
studied in NF pituitary adenomas. A series of pituitary adenoma
proteomic data included 111 proteins identified from an NF
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pituitary adenoma tissue [3], 56 differentially expressed proteins
from 11 NF pituitary adenoma and eight control tissues (Fig. 2)
[1], hormone isoforms (growth hormone and prolactin) (Fig. 3)
[5], and nine nitroproteins and three nitroprotein-protein
complexes from an NF pituitary adenoma tissue (Fig. 4) [6]
and eight nitroproteins from a pituitary control tissue [7, 8].
Signaling pathway networks associated with NF pituitary
adenomas are mined from those whole tissue-proteome varia-
tion data (Fig. 5) [9]. Four important pathway-network systems,
including mitochondria dysfunction, oxidative stress, cell-cycle
dysregulation, and MAPK-signal abnormality, for the NF
adenoma are identified. The follow-up studies of those tissue-
proteome data would contribute to the accurate molecular
classification for the diagnosis of personalized patients and their
personalized treatment. Moreover, the complete tissue-
proteomic databases and body-fluid proteomic/peptidomic data-
bases unique to single-cell type pituitary adenomas and different
pathophysiological stages, must be accurately established, and
the comprehensive computation model system needs to be
developed, towards that PPPM goal.
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Fig. 1. Diagram of the use of proteomic variations to predict, prevent, and personalize treatment for NF pituitary adenomas [2]
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Fig. 3. xMS-characterized GH isoforms in a 2-DE map of human
pituitary. IEF was performed with an IPG dry strip (18 cm, pH 3–10
nonlinear). SDS-PAGE was performed with a polyacrylamide (12%)



































Fig. 2. Functional categories of the 56 DEPs. A. Down-regulated proteins in pituitary adenoma (34): I. neuro-endocrine and hormones; II.
cytokine and cellular signal-related proteins; III. cellular defense and stress resistance; IV. mRNA splicing, transport, or translation-related
enzymes; V. DNA-binding proteins; VI. Metabolic enzymes; VII. Immunologic regulation proteins and tumor-related antigen; VIII. Transport
proteins; IX. cell proliferation, differentiation, and apoptosis-related proteins; X. others. B. Up-regulated proteins in pituitary adenomas (22): I.
metabolic enzyme-related proteins; II. energy metabolism; III. cellular signal proteins; IV. cell cycle, cell growth and proliferation proteins; V.
cellular defense response; VI. protein folding-related protein; and VII. other (taken from [4])
EPMA Journal (2011) 2 (Suppl 1):S103–S118 S105
Adenoma Control
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Fig. 5. Signaling pathway networks of nitroproteins. Network (left) derives from adenoma nitroproteomic data, and functions in cancer, cell
cycle, reproductive-system disease. A gray node denotes an identified nitroprotein, or a protein that interacts with nitroproteins. Network (right)
derives from control nitroproteomic data, and functions in gene expression, cellular development, and connective-tissue development and
function. A gray node denotes an identified nitroprotein. An orange solid-edge denotes a direct relationship between two nodes (molecules:
proteins; genes). An orange nonsolid-edge denotes an indirect relationship between two nodes (molecules: proteins; genes). The various shapes of
nodes denote the different functions. A curved line means intracellular translocation; a curved arrow means extracellular translocation (taken from
[9])
Fig. 4. Model of nitroproteins and their functions in human nonfunctional pituitary adenomas (taken from [6])
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A program is underway to design and implement a liver
tumor treatment program to allow transition from traditional
medical practice toward personalized, predictive and pre-
ventative medicine (PPPM). The assessment, management
and treatment of patients with malignant tumors of the liver
(MTL), within the context of Model-Guided Therapy
(MGT), Patient-Specific Modeling (PSM) and PPPM are
addressed. It is our intention to lay the groundwork and to
describe guidelines so that institutions preparing similar
programs will be able to transition to MGT and to
participate in a multi-center, multi-national consortium for
implementing MGT.
When a patient with MTL is in the care of a treating
physician, attention to their personalized needs is of
paramount importance. Physicians learn to recognize the
individual’s emotional and spiritual needs and desires, and
their physical strengths and weaknesses, which influence
how that physician will form a treatment plan, based on an
assessment and prediction of how that patient will respond
within a given therapeutic regimen. Despite the effort spent
in considering these personalized attributes, due to the lack
of organized programs with specific databases to collect
and analyze this data, little information is available to the
treating physician for use in predicting a single individual’s
survival rate or treatment outcome, when a therapeutic
regimen is offered. As a result, the ability to pursue
personalized medicine is drastically limited.
It is believed that programs can be developed to provide
personalized healthcare. The organization of such a pro-
gram must be able to address the immediate and long term
needs of a patient with (MTL) in an efficient, compassion-
ate and comprehensive manner. Once a potential MTL has
been detected, patients can be thought of as being within
various stages of an MTL Continuum: (1) at risk; (2) MTL
diagnosed and potentially curable; (3) treated and patient
considered cured; (4) MTL treated and in remission; (5)
MTL treated with recurrence or progression of disease; (6)
patient requiring treatment for complications and/or pallia-
tive care; and, (7) advanced MTL requiring end-of-life care.
The patient, at various times during the course of their
disease and treatment, will be found to progress and/or
regress through the various stages of this Continuum.
Therefore, a flexible algorithm needs to be developed to
assist in the guidance of patients through these stages.
Programs for personalized healthcare must record patient
attributes, clinical observations, and therapeutic responses
in databases specifically developed for these purposes.
Comprehensive information will be necessary for statistical
analysis of individual patient characteristics and responses
to therapeutic regimens, and to allow validation of
personalized healthcare delivery and to provide the raw
data for the development and testing of a comprehensive
PSM. It is further postulated that the statistical analysis of
an increasing number of PSM’s will provide the basis for
Model-Based Medical Evidence (MBME), which may
provide a solid foundation for PPPM.
The program covers: (1) Diagnostic criteria and treatment
algorithms; (2) Medical treatment; (3) Surgical treatment;
(4) Interventional Radiology; (5) Radiation Oncology; (6)
Database Development.
THE GLUTATHIONE-S-TRANSFERASE (GST) P1
313G IS A RISK ALLELE FORTHE DEVELOPMENT
OF GRADE ≥2 NEUROTOXICITY IN PATIENTS
TREATED WITH OXALIPLATIN
Del Re M1, Schirripa M2, Loupakis F2, Silvestris N3,
Colucci G3, Falcone A2, Danesi R1
1Division of Pharmacology, Department of Internal Medicine,
University of Pisa, Italy
2Division of Oncology, Department of Oncology, Transplants
and Advanced Technologies in Medicine, University of Pisa,
Italy
3Medical Oncology Department, National Cancer Institute
“Giovanni Paolo II”, Bari, Italy
Background: Oxaliplatin is frequently used in the treatment
of colorectal cancer in combination regimens with fluo-
ropyrimidines. Severe neurotoxicity is the dose-limiting
adverse reaction in patients receiving oxaliplatin and a
potential reason for treatment discontinuation. The main
metabolic route of oxaliplatin detoxification is the conju-
gation with glutathione by the enzyme glutathione-S-
transferase (GST) P1 subclass. GSTP1 displays a polymor-
phism at codon 105 (313A>G or Ile105Val) with high
prevalence: Ile/Ile (45–50%), Ile/Val (42–46%) and Val/Val
(9–11%) (Kweekel et al. 2005). The 313G allele encodes a
variant GSTP1 protein with a lower enzymatic activity for
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the conjugation of various cytotoxic drugs as compared to the
wild type allele (Watson et al. 1998). Previous studies have
investigated the association of GTSP1 Ile105Val polymor-
phism with oxaliplatin toxicity, but the results of these studies
were controversial and the role of the GSTP1 as a biomarker
of susceptibility to develop neurotoxicity is not clear.
Aim: The aim of this study was to investigate the
association of GSTP1 polymorphism Ile105Val with
oxaliplatin-related neurotoxicity in advanced colorectal
cancer patients.
Materials and methods: Germline DNAwas extracted from
27 colorectal cancer patients treated with capecitabine-
oxaliplatin and suffering from neurotoxicity of at least
grade 1; 10/27 patients were affected by neuropathy grade
2–3 (37%). Toxicity was graded using WHO criteria and
GSTP1 313A>G was determined by Real-Time PCR.
Results: Genotype frequency was 11/27 (40.7%) for
homozygous wild-type 313AA and 16/27 (59.3%) for
heterozygous 313AG. No subjects showed the homozygous
variant genotype. There was no significant prevalence of a
specific genotype in these subjects; however, in the
subgroup of patients with neuropathy grade ≥2 there was
a higher prevalence of the heterozygous 313AG (70%) over
the wild-type 313AA (30%).
Conclusions: The results of this study suggest that the 313G
is a risk allele and carriers of the GSTP1 313AG were more
prone to suffer from grade ≥2 neurotoxicity than carriers of
wild type GSTP1 313AA genotype. The small number of
patients in this study needs to be extended in additional
prospective studies, but the present finding suggest that a
pharmacogenetic approach may be an important tool for
optimizing chemotherapy in patients with colorectal cancer
treated with oxaliplatin.
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Why early and predictive diagnostics is crucial
for long-term outcomes of breast cancer?
Breast cancer is the most common cause of cancer-related
death among women with an average incidence rate of 10–
12 per 100 women. Advanced stages of breast cancer lead
to development of metastasis predominantly in lymph
nodes, bone, lung, skin, brain, and liver. In 2005, breast
cancer led to 502,000 deaths comprising 7% of cancer-
related deaths and almost 1% of all deaths worldwide.
Currently applied diagnostic approaches are frequently
unable to recognize early stages in tumor development that
impair the outcome. At present breast-MRI is the most
sensitive diagnostic tool for breast imaging; however, its
specificity is limited resulting in a negative impact for
surgical management in approximately 9% of cases. Early
diagnosis has been demonstrated to be highly beneficial for
significantly enhanced therapy efficiency and possibly full
recovery.
Development of non-invasive subcellular imaging andmolecular
diagnostic approaches for breast cancer risk assessment
Individualized treatment algorithms and paradigm change
from a late interventional approach to predictive diagnostics
followed by the targeted prevention of a disease before it
manifests, presents an innovative concept for advanced
healthcare that is costs effective. Particularly attractive are
non-invasive diagnostic approaches considering disease-
specific alterations in molecular patterns of blood cells and
serum in predisposed individuals before clinically disease
onset.
Group-characteristic patterns: Construction of diagnostic
windows
The central idea of diagnostic windows is to create a
reliable tool that allows for
& Predictive selection of cancer-predisposed individuals
& Early cancer diagnosis
& Identification of individuals at low risk of breast cancer
development, so-called negative prediction.
Considering the comet-fraction patterns characteristic for
individual groups of comparison, the construction of
diagnostic windows for breast cancer risk assessment is
proposed (Fig. 1)
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Fig. 1. demonstrates statistically significant diversities in comet-class IV
(apoptotic DNA) patterns among four groups of comparison (G1 and G2
correspond to pre- and post-menopausal patients with benign breast
alterations, and correspond to G3 and G4 pre- and post-menopausal
patients with breast malignancies, respectively). The group-characteristic
windows are well-distinguishable. Remarkable similarities between both
patient groups 3 and 4 can be seen and potentially used as the pathology-
characteristic windows (red-marked zones). Noteworthy, the distribution
patterns of the group of risk 1 demonstrates intermediate values between
group of risk 2 on one side, and patient groups on the other side. The
group of risk 1 demonstrates also an abundant number of individuals with
extremely high apoptotic level. Data taken from [1]
The diagrams in Fig. 2 summarize a potential predictive
power of the constructed diagnostic windows. Diagram
(A) shows the frequency (%) of patients for each of 4
groups of comparison that have been monitored for
corresponding contingent of the comet-class I in one of
the diagnostic windows. The same—for comet class IV
in the diagram (C). In contrast, diagrams (B) and (D)
demonstrate the frequency (%) in corresponding windows
for combined (G1+G2 versus G3+G4) patient groups.
Obviously, the diagnostic windows with the comet-class
IV patterns can be effective only, when the hormonal
status (pre- and post-menopausal) is considered as one
of the selection parameters for subgrouping the patients
and concomitant utilizing of the approach proposed by
this study.
Pathology-specific comet-patterns as innovative concept of
breast cancer risk assessment: Construction of diagnostic
windows
The add-value of this study is the innovative concept of the
qualification of pathology-specific comet-patterns. The
achieved results have fully supported our hypothesis: some
of the comet-patterns are highly specific for patients at high
risk, whilst other diagnostic windows are highly specific for
individuals at low risk. Whereas predictive diagnostic
windows for patients at high risk are important to recognize
the pathology before it manifests, the diagnostic windows
Fig. 2. Diagrams estimating a predictive power of the constructed diagnostic windows; data taken from [1]
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for individuals at low risk should help to avoid undesirable
treatments and invasive approaches in the case of non-
predisposed individuals. This negative prediction is not less
important compared to a positive predictive diagnosis in
terms of promoting the individualized / correct patient
treatments.
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BIOMARKER DISCOVERY: CHALLENGES AND
OPPORTUNITIES
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Translational Cancer Therapeutics Laboratory, CR-UK
London Research Institute, 44 Lincoln’s Inn Fields,
London, UK
Despite the wealth of published biomarkers in the literature,
recently estimated at over 150,000, approximately 100 are
in routine clinical use. Predictive biomarker identification
in cancer medicine in order to identify patients with drug
sensitive disease improves the health economic costs of
drug therapy. Importantly, evidence suggests that successful
identification of a predictive biomarker can minimise the
use of ineffective therapy in the biomarker negative patient
cohort. Associative learning approaches to predictive
biomarker discovery are subject to data overfitting and
have not resulted in the implementation of clinically useful
biomarkers predictive of drug response. Functional
genomics identification of drug sensitivity mechanisms
using RNA interference may support novel biomarker
discovery approaches. The EU framework 7 funded
PREDICT consortium is taking a novel approach through
the implementation of pre-surgical clinical trials for tumour
genomics analysis with parallel laboratory functional
genomics screens to identify the tumour and stromal
genomics basis for drug response. Caveats to this approach
and tumour biological mechanisms impeding the imple-
mentation of personalised medicine will be discussed.
PREDICTIVE AND PROGNOSTIC MEDICINE: THE
ROLE OF KRAS AND BRAF MUTATIONS AS BIO-
MARKERS IN COLORECTAL CANCER
Hagan S1, Doyle B2
1Department of Vision Sciences, Glasgow Caledonian
University, Glasgow G4 0BA, Scotland
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In developed countries, colorectal cancer (CRC) is the 3rd most
common malignancy and 2nd most frequent cause of cancer-
related death. It therefore offers numerous challenges to
clinicians in treatment regime decision-making. A recent
genome-wide analysis of tumours showed that 20–100
protein-encoding genes were mutated. It is thought that a small
number of these genes may be critical in driving cancer
progression. However, many cancer-causing mutations are
subtle missense mutations that cannot be easily detected by
conventional protein analysis (western blotting, ELISA). KRAS
(and also BRAF) is one of the most commonly mutated cancer
genes, but no single antibody is available that can reliably
differentiate normal from mutated versions of the protein.
Understanding the mutational status of these genes may provide
prognostic information in CRC. More importantly, it has it
appears that KRAS and BRAF mutations predict response to
anti-EGFR monoclonal antibody therapy. As EGFR can also
signal via the PI3-Kinase pathway, there is considerable interest
in the potential roles of members of this pathway (such as PI3-
Kinase and PTEN) in predicting treatment response. Therefore,
new techniques that allow identification of these “biomarkers”
will aid in the diagnosis of cancer, help in treatment decision
making and may also serve as future therapeutic targets.
EARLY CANCER DIAGNOSIS AND NOVEL THER-
APEUTIC OPTIONS RESULTING FROM SYSTEM-
ATIC PROTEOME PROFILING OF TUMOUR-
ASSOCIATED STROMA CELLS
Paulitschke V1, Haudek-Prinz V 2, Slany A 2, Mohr T 2, Griss
J 2, Gerner C2
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The discovery of novel biomarkers is essential for the
improvement of virtually all therapies as well as the early
detection of malicious diseases. Nevertheless, most bio-
markers discovered so far have not satisfied the hopes laid
upon them.
In contrast to most other proteomics research groups we
do not only focus on blood serum and whole tissue
samples but have started to systematically investigate
sub-cellular fractions of different cell types in different
functional states creating a “protein-atlas” of primary
human cells. We believe that only if we know what is
“normal” for a cell in different functional states we will be
able to deduct specific pathological changes that qualify
as biomarkers.
Over the last 6 years we have performed over 10,000 nano-
LC-MS/MS experiments studying 70 distinct cell types,
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isolated from 16 different tissues in 81 different functional
states identifying a total of 10,340 distinct proteins. A focus
of this work was the systematic investigation of the
contribution of non-parenchymal stroma cells to tumour
promotion and the relation of these processes to inflamma-
tion. Therefore we established proteome maps of various
tumour cells, normal as well as tumour-associated fibro-
blasts and endothelial cells from bone marrow, colon, lung,
liver and skin. Furthermore, we investigated well-defined
functional cell states by treating cells in vitro with IL-1beta
or TGF-beta, respectively. Indeed, some proteome alter-
ations observed in tumor-associated cells were related to
inflammation and wound healing activities. Intriguingly,
some features of tumour-associated stroma cells appeared to
be common irrespective of the individual donor and tissue
of origin and unrelated to the proteome signatures of
inflammation or wound-healing. This pointed to general
mechanisms of tumour-stroma interactions which may be
recognised and specifically targeted by appropriate thera-
peutic interventions. Furthermore, this aberrant cell pheno-
type was accompanied by the secretion of a characteristic
set of proteins which may serve as biomarkers. Currently
we are establishing sensitive and robust quantification
strategies for the assessment of these biomarkers in blood
serum. We have started a clinical study of melanoma
patients for clinical validation of our results.
PREDICTION AND PROGNOSIS: IMPACT OF GENE
EXPRESSION PROFILING IN PERSONALIZED
TREATMENT OF BREAST CANCER PATIENTS
Mallmann MR1,2, Staratschek-Jox A2, Rudlowski C1,
Braun M1, Gaarz A2, Wolfgarten M1, Kuhn W1, Schultze JL2
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Integrated Oncology, University Hospital Bonn, Sigmund-
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Breast cancer is the most common cancer of women and a
complex disease, whose heterogeneity is increasingly
recognized. Despite considerable improvement in breast
cancer treatment and survival, a significant proportion of
patients seems to be over- or undertreated with current
therapy. To date, single clinicopathological parameters show
limited success in predicting the likelihood of survival or
response to endocrine therapy and chemotherapy. Conse-
quently, new gene expression based prognostic and predic-
tive tests are emerging that promise an improvement in
predicting survival and therapy response. Initial evidence
has emerged that this leads to allocation of fewer patients
into high-risk groups allowing a reduction of chemotherapy
treatment. Moreover, pattern-based approaches have also
been developed to predict response to endocrine therapy or
particular chemotherapy regimens. Whereas most of these
approaches are at the stage of translational research, several
are ready to be implemented into clinical practice. Irre-
spective of current pitfalls such as lack of validation and
standardization, these pattern-based biomarkers accelerate
identifying novel molecular targets and will prove useful
for clinical decision making in the near future, especially if
more patients get access to this form of personalized
medicine.
VNTR AT HER2/NEU GENE AMPLIFICATION
BORDER IN BREAST CANCER—THE “WEAKEST
LINK” IN GENE AMPLIFICATION?
Kovalenko SP, Matsenko NY
Institute of Molecular Biology and Biophysics, 630117,
Novosibirsk, Russia
Overexpression and amplification of the HER-2/neu gene is
observed in 20–30% of breast cancer cases and predicts
more frequent relapse and shorter survival time. The initial
events and molecular mechanisms of amplification in the
region around HER2/neu as well as the precise boundaries
of amplified regions remain to be obscure. This study was
aimed to define the boundaries of amplified chromosome
17q12-q21 region around HER2/neu gene. Structural
peculiarities of amplification boundary regions were inves-
tigated by various techniques.
Gene dosage analysis was performed for several genes
located around HER2/neu gene in 154 breast cancer tissue
samples. The copy number of genes around Her2/neu,
namely ppparbp, znfn1a3 Casc3 and top2a genes were
analyzed by comparative TaqMan real time PCR. Fifty six
samples (36%) were found to be her2/neu-amplified
(NHER2/neu≥1,5), the boundaries for HER2-containing
amplicons were mapped.
Observed results suggest that similar positions of amplified
region boundaries in different breast cancer samples are not
accidental and may be related with the DNA structural and/or
sequence peculiarities of boundary regions. Trying to find
“special” sequences at the amplicon boundaries, we performed
the analysis of sequence flexibility in the region TBC1D3–
HER2/neu – TOP2A using the TwistFlex program. The
analysis revealed several high flexible sequences in SOCS7,
FBX047, HER2/neu and ZNFN1A3 genes. The locations of
amplified region boundaries in 30% of cases were inside
ZNFN1A3 gene. Organization of DNA sequence and nucle-
otide composition ofFlexZNF-1 and FlexZNF-2 were similar
to AT-rich islands of common fragile site (FS). Sequences of
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FlexZNF-1 and FlexZNF-2 have strong potential to form
secondary structures according to the analysis by Mfold
software (GCG Wisconsin Package™).
Thus, the analysis of DNA sequence in TBC1D3– HER2/
neu – TOP2A region revealed the existence of two flexible
sequences in theZNFN1A3 gene sequence with the strong
potential to form stable secondary structures which may
affect normal DNA replication at these sites and result in
DNA double strand break appearance. The location of
FlexZNF-1 and FlexZNF-2 strongly coincided with the
location of amplified around HER2/neu gene fragment
boundaries observed by real time PCR analysis.
This observation indicates involvement of Flex sites in
the process of intrachromosomal DNA amplification.
Since FlexZNF-1 and FlexZNF-2 sites are mainly com-
posed from tandem repeats, the variability of repeats
numbers in the regions was analyzed in the local
population. At least two allelic variants were found, so
amount of repeats is genetically predetermined feature. We
assume that the length of the Flex site on the border of
HER2/neu amplificon can be considered as the essential
point in the process of intrachromosomal amplification
around HER2/neu gene.
To summarize the results of the investigation:
– The borders for HER2/neu amplification were precisely
localized at least in 30% cases;
– The borders of amplification were shown to contain
repetitive highly flexible sequences;
– The number of repetitive sequences at the borders of
HER2/neu amplification varies in population.
PREDICTIVE VALUE OF DOMINANT NODULE IN
HASHIMOTO THYROIDITIS. A CLUE FOR A PER-
SONALIZED APPROACH FOR GREATER RISK OF
PAPILLARY THYROID CARCINOMA
Trovato G, Amico P, Martines GF, Castaing M, Torrisi A,
Vecchio GM, Salvatorelli L, Catalano D, Magro G
Department G.F. Ingrassia, Anatomic Pathology, and Depart-
ment of Internal Medicine, Diagnostica e Terapia Medica,
“University of Catania, Catania, Italy
Hashimoto’s Thyroiditis (HT) or chronic lymphocytic
thyroiditis is an autoimmune disease in which the thyroid
gland is gradually destroyed by a variety of cell- and
antibody-mediated immune processes. HT can undergo
morphological changes over the time, resulting in at least
three different histological variants (classic, nodular or
fibrotic variant). Interestingly some patients with HT may
develop one or more nodules larger than >1 cm, so-called
dominant nodules (DNs). Due to the association between
HT and papillary thyroid carcinoma (PTC), the detection of
DNs is alarming, prompting physicians to perform fine
needle aspiration cytology (FNAC) to rule out malignancy.
The incidence, nature (benign vs. malignant) and clinical
impact of DN in HT is still controversial.
The aim of the study is to investigate: (1) the clinicopath-
ological features of DN in HT; (2) the prevalence of DNs
that are actually PTC; (3) the predictive value of DN for
a concurrent PTC occurring elsewhere in the thyroid
gland.
Patients and methods: We reviewed 230 consecutive cases of
thyroidectomy (partial or complete), age 48.44±11.05 years
(range 24–80) with a clinical and histologically proven
diagnosis of HT. Histological revision of all hematoxylin/
eosin (H&E) stained sections was performed. Any nodule,
grossly reported (original pathology report) and histologically
confirmed, with a diameter ≥1.5 cm, merging from the
surrounding thyroid parenchyma, was conventionally defined
as a DN.
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Results: Among the 230 cases of HT 69 showed at least one
DN (≥1.5 cm). Histologically most of DNs (57/69, 82.6%)
where benign lesions, i.e. hyperplastic follicular nodules
(HFNs), while only 12 DNs (17.4%) were PTC. HFNs were
composed of Hurthle or non-Hurthle cells, with or without
association with chronic inflammation.
PTC was present in other part of the thyroid gland in 17/57
(29.8%) of the patients with a benign HFN-DN, and in 18/
161 (11.2%) patients with HT but without any DN.
The Odds-ratio to PTC showed a four-fold increased risk to
PTC when the thyroid exhibits a DN, and a lower risk in
older patients.
Also excluding DN that were actually PTCs, the Odds-ratio
showed an increased risk to PTC for patients with a HFN- DN
By MLR, the absolute dimension of the nodule is predictive
of malignancy. This model, moreover, predicts 18.2% of the
variance to the dimension of PTC.
Table. Multiple Linear Regressions to PTC dimensions (cm)
R R2 F sig β p
0,427 0,182 16,690 <0,0001





PTC: Papillary Thyroid Carcinoma; DN: Dominant Nodule
(≥ 1,5 cm)
Comments
1) Only a minority of DNs in HT are actually PTCs. Most
DNs are hyperplastic follicular lesions that could be
clinically managed, avoiding unnecessary surgery.
2) Nonetheless, the presence of a DN in HT, even if
benign, increases four-fold the risk of PTC. A
seemingly protective effect is associated with an older
age in these patients.
3) Also HFN-DNs, i.e. lesions that conceivably should have
been assessed benign at FNAC, increase, even at a lower
extent, the risk for PTC elsewhere in the thyroid gland.
Conclusion: A great care in the use of imaging information as
predictive tools for PTC in large DNs of HT is warranted.
IDENTIFICATION OF CALPONIN-H2 AS POTEN-
TIAL SERUM-BASED MARKER FOR THE EARLY
DIAGNOSIS OF BREAST CANCER
Debald M1, Franken S2, Heukamp LC3, Linke A4,
Wolfgarten M1, Walgenbach KJ 1, Rudlowski C1,
Holdenrieder S4, Braun M1, Hartmann G4, Kuhn W1,
Walgenbach-Brünagel G4
1Department of Obstetrics and Gynecology, Centre for
Integrated Oncology, University of Bonn, Germany
2Institute for Biochemistry and Molecular Biology, University
of Bonn, Bonn, Germany
3Institute of Pathology, Centre for Integrated Oncology,
University of Bonn, Germany
4Institute for Clinical Chemistry and Clinical Pharmacology,
Centre for Integrated Oncology, University of Bonn, Germany
Purpose: To date, clinical breast examination, imaging by
mammography as well as tumor biopsy are the only
recommended methods for breast cancer screening, while
mainly clinicopathological parameters determine the adju-
vant therapy of this disease. In order to implement a
personalized management of breast cancer patients, reliable
biomarkers are urgently needed to improve the early
detection or provide evidence of the prognosis for each
individual patient through expression levels in tumor tissue
or body fluids.
Methods: The nuclear matrix composition of human breast
cancer tissue (n=14), benign control tissues (n=2) and
healthy control tissues (n=2) was analyzed by high-
resolution two-dimensional gel electrophoresis and mass
spectrometry. The identified proteins were validated by one-
dimensional immunoblot in an individual sample set. A
sandwich ELISAwas used to determine the serum levels of
calponin-h2 in breast cancer patients (n=11) and healthy
controls (n=5).
Results: In this setting, we identified five proteins that were
upregulated in human breast cancer tissue (14/14), but
absent in any of the four healthy and benign control tissues
(p=0,0003). These spots were also present in the investi-
gated human breast cancer cell lines outlining the epithelial
character of the identified proteins. One of these breast
cancer specific proteins has been confirmed to be Calponin-
h2 by mass spectrometry and one-dimensional immunoblot
in an individual sample set of three additional breast breast
cancer tissues and two additional healthy control tissues.
Compared to healthy controls, serum levels of calponin-h2
were significantly increased in patients with early breast
cancer (p=0,022).
Conclusion: In an effort towards personalized and
predictive medicine in breast cancer, Calponin h2 has
been shown to be a potential serum-based marker for
the early diagnosis of this disease. Further studies are
ongoing to validate these promising results in a larger
sample set.
PHARMACOGENOMICS IN CANCER THERAPY
González Neira A
Spanish National Cancer Research Centre (CNIO), Madrid,
Spain; EPMA-Spain
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Although the current cancer therapies are improving
rapidly, it is often hindered by drug resistance and
treatment-related toxicities. Interindividual and interethnic
variability in drug pharmacokinetics and pharmacodynam-
ics may be explained by commonly occurring genetic
polymorphisms in drug-metabolizing enzymes and drug
transporters. Although to date pharmacogenomics stud-
ies have been focused on a reduced number of genes,
the development of the new technologies are allowing
us to focus these studies on the integration of multiple
drug pathways and also to perform analysis at the
genome-wide level. These new approaches allow a more
comprehensive analysis of genetic factors influencing
drug efficacy and toxicity in breast cancer and could
reveal possible unknown mechanisms involved in drug
response.
TUMOUR PROGRESSION PROGNOSIS AND
ENGINEERING OF INDIVIDUALISED CLINICAL
TREATMENTS FOR MALIGNANT GLIOMAS
Trog D, Yeghiazaryan K, Schild HH, Golubnitschaja O
Department of Radiology, Rheinische Friedrich-Wilhelms-
University of Bonn, Germany
Malignant gliomas are highly lethal cancer disease. Thus,
median survival of 14.6 and 12.1 months was demonstrated
when either chemoradiation or radiation alone had been
applied. Irrespective of the treatment, glioblastoma patients
have been shown to benefit from epigenetic silencing of
MGMT (O6-methylguanine-DNA-methyltransferase) ex-
pression, DNA-repair activity of which was compromised
by promoter methylation (an independent favourable
prognostic factor associated with longer survival in patients
with glioblastoma). The fact that those patients whose
tumours are not methylated at the MGMT-promoter do not
benefit from temozolomide (TMZ) treatment, suggests a
predictive role of MGMT methylation status in therapy
response towards TMZ-treatment. For these patients,
alternative treatment approaches should be applied. How-
ever, under TMZ-treatment significant differences in sur-
vival (range of 17 to 30 months) have been demonstrated
even for patients whose tumours were methylated at the
MGMT-promoter. Depending on the patient, individual data
measured in the primary human glioblastoma cells showed
a wide range of response to TMZ treatment in vitro. This
finding calls for further predictors of individual therapeutic
responses in treated glioblastomas. Therefore, molecular
mechanisms of therapy resistance are of particular interest
in malignant glioblastomas with a hypermethylated
MGMT-promoter.
Engineering of individualised clinical treatments for malig-
nant gliomas guided by individual molecular profiling is
particularly relevant for the creation of improved post-
operative treatment of peripheral tumour regions, the
diffuse character and disseminated growth of which make
the treatment of malignant gliomas especially complicated.
It has been clearly documented that current post-operative
therapeutic approaches may favour peripheral tumour
progression and select for a more aggressive relapse than
before these treatments were introduced as the standard
care. Consequently, the specific expression patterns forcing
pro-invasive and pro-angiogenic activity of malignant cells
were found to be characteristic particularly for the treated
tumour periphery as simulated by the above described
algorithms. These results strongly support the clinical
observations of increased aggressiveness and relatively
poor response to second line therapies in post-operative,
chemoradiation-treated, malignant gliomas at the time of
relapse. In addition to the methylation status of MGMT-
promoter, tumour patterns combining expression levels of
the pathology-specific genes reported might be useful for
the prediction of individual therapy response and disease
progression in malignant glioblastomas with a hypermethy-
lated MGMT-promoter. Individualised treatment algorithms
can be designed using established gene expression patterns
applied to primary cell cultures obtained from individual
patients. Individual drug-toxicity and response to anti-
cancer therapy can be estimated.
General progress in treatment of brain tumour patients is
expected by introducing directed therapy approaches
which would specifically suppress the activity of molec-
ular targets of glioma invasion in order to control
invasive cell subpopulations escaping surgical removal
and lethal radiation exposure.
TOWARDS A PERSONALIZED PARADIGM OF
EXPERIMENTAL ANTICANCER RESEARCH
WITH “3S” CONCEPT
Moiseeva EV, Semushina SG, Bojenko VK
Institute of Bioorganic Chemistry, Moscow, Russian
Federation
Earlier, we developed three novel inbred mouse strains
(RB-strains, carriers of Rb(8.17)1Iem Robertsonian trans-
location). They exhibited various but high incidences of
spontaneous mammary cancer (MC) rarely associated with
ovary/uterus cancer and/or leukaemia/lymphoma. New
classification of mouse MC has been worked out to disclose
similarities with human breast cancer (BC) pathology. Our
way to follow each laboratory mouse during its life-span
individually (as a patient) and original approaches to test
anticancer drugs (ACD) have been developed during last
two decades [1]. This direction towards a personalised
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paradigm of experimental research has been currently
resulted in “3S”concept:
The 1st S: Set of non-SPF mouse strains as an adequate
model of familial aggregation of human breast cancer
with multiple cancer cases and leukaemia/lymphoma;
The 2nd S: Steps of experimental research in vitro
(cancer and immune cells separately) and in vivo:
transplanted (preliminary tests to discover proper
dosage, application time, et cetera), spontaneous
(therapeutic application in females with spontaneous
MC with/without tumour extirpation), and precancer-
ous (preventive regimen in females before spontaneous
MC occurrence);
The 3rd S: Subgrouping approach to disclose beneficial
and non-beneficial subgroups in both experimental and
control groups concurrently and to show both positive
and negative effects of ACD, respectively.
Several experimental areas of our research should be
mentioned to illustrate our concept validity in relation
to personalized/predictive/preventive medicine (“3P”
medicine).
First of all, adequacy of our mouse models was approved
by histopathology (evident similarity of some mouse
mammary carcinoma types to corresponding types of
human BC). Furthermore, apparent analogies in recurrence
rate and survival in relation to the stage of mouse MC to
corresponding parameters for human BC patients were
revealed after surgery. Moreover, we found similar predic-
tive values of particular histopathologic patterns of extir-
pated murine MC samples to related patterns of human BC.
In both species, “comedo” mammary carcinoma patterns
predict early recurrence and/or poor survival; and medullar
carcinoma is characterized by extensive leukocyte infiltra-
tion and unexpectedly good outcome.
Moving further to “3P” conception of modern medicine, we
showed that some laboratory blood and serum parameters
(i) predicted subclinical period of murine MC (time before
transplanted tumour manifestation); (ii) correlated with a
stage of tumour growth in transplanted models; and (iii)
allowed to forecast time of spontaneous MC detection in
precancerous females of RB-strains. Additionally, some
laboratory parameters (related to anaemia and chronic
inflammation in the murine liver/kidney/lung/hart) were
associated with beneficial or non-beneficial effects of
immunotherapy by local interleukin-2.
Importantly, non-SPF mice (especially, aged animals) show
chronic inflammation in many organs similarly to the
majority of human BC patients. For instance, viral hepatitis
does interfere with treatment procedures in both species.
These data may (i) imply failure of SPF mouse models to
reproduce concurrent pathologies in human BC patients and
(ii) approve non-SPF ones as appropriate mouse models for
preclinical ACD testing.
In summary, we showed utility of “3S” concept on the way
to personalized experimental anticancer research.
Reference:
1. Moiseeva E. Anti-breast cancer drug testing. Original approaches.
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The ability of tumors to provoke formation of cancer-
associated secondary immunodeficiency (CASID) with pre-
dominant suppression of CMI and cancer-associated second-
ary immunodeficiency with clinical autoimmunity syndrome
(CASICAS) with triggering of a set of the autoimmune
deviations is appearing to be a key event in the restriction of
hosts’ anti-tumor immunity. In order to reach a point where
immunological phenotypes in GBM and BCC can be clarified
clinically and, partly, pathogenically, we have conducted a
series of studies of typical and atypical types of immune
responsiveness in patients with GBM (Glioblastoma multi-
forme) and BCC (Basal cell carcinoma). For GBM and BCC
three scenarios of the involvement of the immune responsive-
ness have been established in a series of our studies, i.e., (i)
malignancy with no immunopathology, (ii) malignancy as
CASID, and (iii) malignancy as CASICAS. All of those
scenarios demonstrated significant differences in their
immune-mediated manifestations which, in turn, were proven
to reveal close associative relationships with a specific
clinicopathologic type and clinical manifestations of the
tumor. CASID and CASICAS share two common features, i.
e., (i) signs of immunodeficiency and (ii) a tandem of the
deviations within the adaptive and innate links of the host
immune responsiveness. At the same time, CASID and
CASICAS are distinct pathogenically and clinically, and in
terms of depth of the immune deviations observed, CASID
patients manifest a breakage in both links, whereas in
CASICAS patients, a breakage in the adaptive link would
dominate. To get these differences clarified, we summarized
major types of the immune imbalances and sets of clinical and
clinicopathologic manifestations to illustrate the above-
mentioned features in CASID and CASICAS patients. There
are distinct close correlations between clinicopathologic
features of the disease course and sets of the immune-
mediated imbalances in patients harboring the tumors. The
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latter implicates a panel of the new immunodiagnostic and
immunoprognostic criteria for patients with solid tumors, i.e.,
BCC, MCC and GB, which is of great value for clinical
practice.
In particular, the blood levels of some of the immunocom-
petent cells, state of their functional activity, serum titers of
the antigenic markers and autoantibodies, apoptotic param-
eters, and others may be accepted as additional and
clinically informative criteria to be implemented for
immunological monitoring and immunotherapy of patients
with solid tumors.
PROGNOSTIC SIGNIFICANCE OF MIR-21 AND
MIR-143 EXPRESSION IN TISSUE SAMPLES OF
COLORECTAL CARCINOMA AND COLORECTAL
LIVER METASTASES
Pešta M1, Topolčan O1, Kulda V 2, Řehoř L2, Svatoň M 2,
Holubec L1, Černý R 2, Liška V 3
1Department of Internal Medicine II, Faculty of Medicine in
Pilsen, Charles University in Prague, Czech Republic
2Department of Biochemistry, Faculty of Medicine in
Pilsen, Charles University in Prague, Czech Republic
3Department of Surgery, University Hospital and Medical
Faculty in Pilsen, Czech Republic
MicroRNAs, which are endogenously expressed regulatory
noncoding RNAs, have an altered expression in colorectal
cancer.
The aim of our study was to assess a potential link between
miR-21 and miR-143 expression and the prognostic /
clinical / pathological features of colorectal carcinoma
(CRC) and colorectal liver metastases (CLM).
Methods: The estimation was performed in 46 paired
(tumour and control) tissue samples of CRC. We studied
30 tissue samples of CLM. miR-21 and miR-143 expres-
sions were quantified using the method of RT qPCR.
Results: A correlation between miR-21 and miR-143
expression and a disease-free interval (DFI) (Wilcoxon;
P=0.0026 and P=0.0191, respectively) was identified. DFI
was shorter in patients with a higher expression of both
miR-21 and miR-143, which is a putative tumour suppres-
sor. There was a higher expression of miR-21 and lower
expression of miR-143 in CRC tissue in comparison with
adjacent normal colon tissue (P<0.0001; P<0.0001, re-
spectively). Similarly, we observed a higher expression
of miR-21 and a lower expression of miR-143 in CLM
in comparison with normal colon tissue (P<0.0001;
P<0.0001, respectively).
Conclusion: Our results support the hypothesis about
oncogenic / tumour-related function of miR-21 and show
its association with DFI. The role of miR-143 in carcino-
genesis seems to be more complex than it has been
expected.
This study was supported by grants NS 10240-3/09 and
Nr. 10230 from the Ministry of Health of the Czech
Republic.
VITAMIN D AND CANCER DISEASES
Fuchsova R, TopolcanO, Pazdiora P, Svobodova S, Vrzalova J,
Krakorova G, Spisakova M, Treska V, Treskova I, Pesek M,
Finek J
Faculty Hospital and Medical Faculty in Pilsen, Charles
University, Czech Republic
Vitamin D is a fat-soluble steroid prohormone which plays
a major role in the calcium and phosphorus homeostasis. It
is known that most cells express Vitamin D receptor and
about 3% of the human genome is directly or indirectly
regulated by Vitamin D. However, 40 to 75% of the world’s
population is Vitamin D deficient. Vitamin D levels have
been associated with many disorders, diseases and related
outcomes: osteoporosis, cancer, cardiac risk, autoimmune
and reumatoid diseases, transplant patients, ect. The aim of
our study was to determine the frequency of vitamin D
hypovitaminosis in patients with different malignant cancer
diseases.
Methods: Serum levels of 25-OH vitamin D were measured
using ECLIA immunoassay manufactured by Roche in 215
healthy individuals and in 170 patients with colorectal,
lung, prostate and breast (pre- and postmenopausal) cancer.
Serum levels in cancer patients were compared to healthy
group and further correlated with disease stage within each
diagnosis.
Results: Vitamin D levels were found to be significantly
lower in cancer patients compare to healthy group. 39% of
all cancer patients show values below 47, 5 nmol/L—cut-
offs set as 5th percentile of healthy group. 29% of patients
with colorectal cancer, 35% patients with breast cancer,
64% of patients with lung cancer and 18% of patients
with prostate cancer had levels of D vitamin below cut off
value. Authors have confirmed the correlation between
disease stage and serum levels in patients with colorectal
lung and premenopausal breast cancer. No correlation was
found for postmenopausal breast cancer and for prostate
cancer.
Conclusion: Authors found high incidence rate of severe
hypovitaminosis D in cancer patients among Czech popula-
tion. This rate is significantly higher when comparing
literature data. Correlation with a disease stage was found.
Support: This study was supported by VZ and grants
NS9727-4, NS9998-4, NT11017-5.
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MULTIPLEX PANEL FOR OVARIAN CARCINOMA
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Aim: As a continuation of our pilot study [1] commercially
available xMAP multiplex panel specifically designed for
ovarian cancer is to be tested in larger patient cohorts. The
multiplex panel includes Macrophage Migration Inhibitory




& Fifty patients with ovarian carcinoma
& Seven patients with border line tumour of ovaria
(BTO)
Benign groups:
& Thirty patients with benign ovarian cysts (BOC)
& Thirty patients with endometriosis
& Eleven patients with cardiac insufficiency
Serum levels of multiplex markers were measured by
Beadlyte® Human Cancer Biomarker Panel from Millipore
(USA) and Luminex 100 instrument (Luminex, USA).
Simultaneously, levels of CA125, TK, TPS, HE4 and
Monototal were measured by routine immune analytical
methods.
Results: From the multiplex markers, the best ROC
characteristics were observed for CA125, IGFII and
OPN. HE4 marker had the best ROC characteristic from
all measured markers for differentiation of ovarian
carcinoma and BOC or endometriosis. In the multiplex
panel, significant differences in marker levels between
ovarian carcinoma and BCO were founded for CA125,
OPN and IGFII (lower in carcinoma) and between
ovarian carcinoma and endometriosis for IGFII, OPN,
PRL (for both higher in carcinoma). For OPN, MIF and
HE4 the levels were different in BTO compare to BCO.
CA125 measured either by multiplex or routine method
was higher in endometriosis compare to benign cysts.
Using multi-parametric data handling ROC curves for
multiplex panel (AUC 0.87636) were comparable to
CA125 alone to distinguish between ovarian carcinoma
and BOC.
Conclusion and prospective: Multiplex may enable the use
of a scoring system for clinical use in distinguishing
between several pathologies. However, the choice of
markers used for the panel is crucial.
Support: Study was supported by the research grant project
NS10258-3.
Reference:
1. Vrzalova J, Prazakova M, Novotny Z, Topolcan O, Casova M,
Holubec L Jr. Test of ovarian cancer multiplex xMAP technology
panel. Anticancer Res. 2009; 29: 573-6.
PPPM EARLY IN LIFE: MOLECULAR AND EPIDEMI-
OLOGICAL MODELS FROM PAEDIATRIC CANCER
Rovigatti U
Department of Oncology, University of Pisa Medical
School, Via Roma 55, 56127 Pisa, Italy
In his 2008 Nobel lecture, Harald zur Hausen spends only a
few words on the association of high-risk HPVs with
cervical cancers, although for this discovery his Nobel Prize
was awarded. Instead, his emphasis is placed on additional
and new situations of infectious agents as triggers,
especially of childhood cancers [1]. Infections, which are
being suspected to trigger a higher proportion of paediatric
malignancies, could become a new and important Paradigm
of PPPM Early in Life.
My group has tackled this problem for several years,
starting from seminal observations on cancer clusters, i.e.:
space-time associations of new diagnoses, which have been
extensively studied epidemiologically, mostly in the UK
and US. The work by L. Kinlen has suggested that they
could be explained by population-mixing effects, recog-
nized now in several cancer-clusters [2]. Isolated groups,
for example in rural communities, are unexposed and
therefore susceptible to a still-to-define infectious agent
(probably a virus = X-virus), carried along my immigra-
tions of newcomers. Immigrants typically originated from
more densely inhabited areas: they were exposed to the X-
Agent and therefore protected by “herd-immunity”. The
isolated communities lack such herd immunity and are
susceptible to the cancer-inducing X-agent [2]. A slightly
different model was proposed by M. Greaves, taking into
account the molecular biology of paediatric cancers and
especially leukaemia [3]. Monozygous twins display
sometimes (10% of cases) a genetically identical disease
(identical chromosomal translocation breakpoints): this
could be only explained by metastatic-diffusion of cancer
cells from one twin to the other through placental
anastomoses. Interestingly, disease could be diagnosed in
twins up to 9 years apart. This led to discovering that
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chromosomal translocations are already present at birth
(Guthrie’s cards), although it takes variable time to “express
them” into overt disease [3]. Even more puzzling, such
translocations are present also in the normal population,
although at a lower level (in approx. 50% for the CML
breakpoint and in up to 100% normal individuals for MLL
aberrations) [4]. Greaves model requires two distinct events,
but could be reconciled with Kinlen’s population-mixing if the
X-virus corresponded to the later trigger. We initially studied a
cancer-cluster of Neuroblastoma (NB) cases in Southern
Louisiana and serendipitously discovered a cytoplasmic
Virus: Micro-Foci inducing Virus (MFV) [5]. A similar virus
was isolated from paediatric lymphomas. Experimental
evidence link these viruses to childhood carcinogenesis,
because MFVs: 1. induce malignant transformation in vitro;
2. induce the appearance of specific chromosomal (DNA)
aberrations; 3. cause tumorigenesis in experimental animals.
[6]. The possibility that MFV is the X-Virus or 2nd trigger
implied by Kinlen/Greaves studies is being investigated.
Other experiments link MFVs to the Fatigue Syndromes
often associated to malignancies (CFS/CRF). Recently, the
Retrovirus XMRV was linked to CFS, but this is artefact.
MFV shares the evidence for CFS/CRF trigger including
high induction of RNASEL [7].
In conclusion our MFV model, in association with Kinlen
and Greaves, could provide a more general explanation for
a portion of childhood cancers. In view of the unique
characterization of both MFV genotypes and chromosomal
aberrations (fingerprints), this could become an excellent
PARADIGM of PPPM Early in Life.
References:
1. Zur Hausen, H. The search for infectious causes of human cancers:
where and why. Virology. 2009 Sep 15;392(1):1–10.
2. Kinlen, L. Childhood leukaemia, nuclear sites, and population
mixing. Br J Cancer. 2011; 104: 12–18.
3. Greaves, M. Infection, immune responses and the aetiology of
childhood leukaemia. Nat Rev Cancer. 2006;6:193–203.
4. Bäsecke J, Griesinger F, Trümper L, Brittinger G. Leukemia- and
lymphoma-associated genetic aberrations in healthy individuals.
Ann Hematol. 2002;81:64–75.
5. Rovigatti U. Isolation and initial characterization of a new
virus: Micro-Foci inducing virus or MFV. C R Acad Sci III.
1992;315:195–202.
6. Rovigatti U, Piccin A, Colognato R, Sordat B. Preliminary Character-
ization of a New Type of Viruses Isolated from Paediatric Neuroblas-
toma and Non-Hodgkin’s Lymphoma: potential Implications for
Aetiology. Intn. Conference Childhood Leukaemia. Section P1-18
pp I-IV, September 2004, London, United Kingdom, Editor: CwL.
7. Rovigatti U, Selli C, et al. “Of Mice and Men—1333 Viruses and
Prostate Cancer: What Is the Next Step?”. European Urology.
2010;58(5):684–686.
REGULATION OF THE PHOSPHATASE, PP2A
AS A CLASSIFIER OF CANCER PATIENTS WITH
POTENTIAL SENSITIVITY TO THE PP2A ACTIVA-
TOR, FTY720
Grech G
Department of Pathology, University of Malta, Malta
The importance of feedback mechanisms involved in
suppression of growth factori-nduced signals is gaining
importance both to understand molecular mechanisms of
disease and also as potential targets to specific therapeutics.
The use of biomarkers to derive knowledge required for the
classification of patients into therapeutic groups has been
extensively used in various malignancies. Our studies show
that deregulation of the phosphatase, pp2a is central to
enhanced proliferation of haematopoeitic progenitor cells at
the expense of suppressed differentiation induction. Using
an erythroid progenitor cellular model, we showed that
differentiation can be blocked by constitutive expression of
the pp2a subunit, alpha4. This was mainly through
maintained activation of the mTOR pathway. The block in
differentiation was rescued using the pp2a activator,
FTY720 in the same model. Interestingly, pp2a dephos-
phorylates and suppresses the activity of various signalling
pathways, namely the Akt kinase. Cancer patients with
suppressed phosphatase activity are potentially sensitive to the
pp2a activator, FTY720. In addition to cellular models, our
previous studies on patient material derived from Triple
negative Breast Cancer patients show that patients can be
classified using Akt phosphorylation as a biomarker. High Akt
phosphorylation correlates with low BRCA1 expression, a
mechanism that directly involves the phosphatase pp2a. This
new class of triple negative breast cancer patients might
benefit from therapy directed towards activation of pp2a.
New insights in the mechanism of pp2a regulation form the
basis of potential identification of variants that affect the
phosphatase activity. Further studies will allow association
of these variants with activity of the phosphatase and
identification of biomarkers to screen for such variation.
Characterisation of the mechanisms of pp2a inhibition will
allow classification of patients into therapeutic groups
sensitive to pp2a activators.
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